Omentin-1 vs Methoxy PEG-Epoetin Beta
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and Methoxy PEG-Epoetin Beta (Methoxy polyethylene glycol-epoetin beta (CERA)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Omentin-1 | Methoxy PEG-Epoetin Beta |
|---|---|---|
| Category | Diabetes & Metabolic | Muscle & Performance |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Methoxy polyethylene glycol-epoetin beta (CERA) |
| Molecular Weight | ~35 kDa | ≈60,000 Da |
| Half-Life | hours | ~130 h |
| Amino Acids | 313 | 165 |
| Typical Dose | No approved human dose; research use only | 0.6 mcg/kg SC every 2 weeks or 1.2 mcg/kg SC monthly |
| Route | IV|SC | Subcutaneous/IV |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 95 |
| Research Status | Pre-clinical | Clinical |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Methoxy PEG-Epoetin Beta Benefits
- ✓long-acting erythropoiesis
- ✓stable hemoglobin
- ✓fewer injections
- ✓improved oxygen delivery
Omentin-1 Dosing
not established|not established
Methoxy PEG-Epoetin Beta Dosing
0.6 mcg/kg SC every 2 weeks|1.2 mcg/kg SC monthly|Adjust based on hemoglobin
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Methoxy PEG-Epoetin Beta Side Effects
- ⚠hypertension
- ⚠thromboembolism
- ⚠headache
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Methoxy PEG-Epoetin Beta
Clinical trials show predictable hemoglobin correction with a long dosing interval and sustained red-cell stimulation. Any VO2 max effect would be secondary to higher hemoglobin, not a direct ergogenic mechanism.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.